Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK-IN-22
CAS :<p>ALK-IN-22 suppresses ALK and mutants (IC50: 2.3-3.7 nM), hinders phosphorylation, and induces apoptosis in tumor studies.</p>Formule :C24H24ClN7O2Couleur et forme :SolidMasse moléculaire :477.95RIPK2-IN-1
CAS :<p>RIPK2-IN-1 (compound 18f) is a potent inhibitor of RIPK2 (IC50: 51 nM) and also inhibits ALK2 (IC50: 5 nM).</p>Formule :C23H27N5O3SCouleur et forme :SolidMasse moléculaire :453.56EGFR-IN-59
CAS :<p>EGFR-IN-59: EGFR inhibitor, IC50 = 190 nM, induces apoptosis, cytotoxic to A549 cells (IC50 = 8.62 μM) and WI38 cells (IC50 = 52.6 μM). Use: Various cancers.</p>Formule :C27H23N5O4SCouleur et forme :SolidMasse moléculaire :513.57RET-IN-19
CAS :<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Formule :C28H28N6O4SCouleur et forme :SolidMasse moléculaire :544.62TyK2-IN-2
CAS :<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Formule :C16H18N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :310.35VA5 TG2 inhibitor
CAS :<p>VA5 inhibits transamidase and GTP-binding by locking protein in an open state, disabling GTPase.</p>Formule :C31H34N4O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :590.62ARQ 069
CAS :<p>ARQ 069 inhibits FGFR2 phosphorylation concentration-dependently (IC50: 9.7 µM), without affecting β-actin. Preferentially binds inactive FGFR1/2.</p>Formule :C18H15N3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :273.33JTV-519 free base
CAS :<p>JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic</p>Formule :C25H32N2O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :424.6EGFR-IN-46
CAS :<p>EGFR-IN-46: Potent EGFR/FAK inhibitor (IC50: 20.17 & 14.25 nM), curbs cancer cell growth, triggers apoptosis.</p>Formule :C27H32F3N3O3Couleur et forme :SolidMasse moléculaire :503.56Y 11
CAS :<p>focal adhesion kinase (FAK) inhibitor</p>Formule :C8H17BrN4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :265.15FLT3-IN-6
CAS :<p>FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.</p>Formule :C23H25N5O3Couleur et forme :SolidMasse moléculaire :419.48KBP-7018
CAS :<p>KBP-7018: potent tyrosine kinase inhibitor targeting c-KIT, RET, PDGFR with IC50s of 10, 7.6, 25nM.</p>Formule :C31H30N4O5Couleur et forme :SolidMasse moléculaire :538.59CGI560
CAS :<p>CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.</p>Formule :C29H27N5OCouleur et forme :SolidMasse moléculaire :461.56MBM-55S
CAS :<p>MBM-55S, a Nek2 inhibitor with 1 nM IC50, induces cell cycle arrest and apoptosis, suppressing tumor growth.</p>Formule :C36H39FN6O10Degré de pureté :99.37% - 99.89%Couleur et forme :SolidMasse moléculaire :734.73BMS-243117
CAS :<p>BMS-243117: Selective LCK inhibitor, IC50=1.1µM, inhibits T cell growth, promising for immunosuppression, arthritis, asthma treatment.</p>Formule :C20H21ClN4O2SCouleur et forme :SolidMasse moléculaire :416.92BTK-IN-9
CAS :<p>BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.</p>Formule :C25H19N7O4Couleur et forme :SolidMasse moléculaire :481.46JAK-IN-14
CAS :<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Formule :C19H15FN4ODegré de pureté :98.27%Couleur et forme :SolidMasse moléculaire :334.35JAK-IN-18
CAS :<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formule :C27H28F2N6O3Couleur et forme :SolidMasse moléculaire :522.55HZ-A-005
CAS :<p>HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.</p>Formule :C25H23ClN6O2Couleur et forme :SolidMasse moléculaire :474.94ALK-IN-21
CAS :<p>ALK-IN-21 (B10) inhibits ALK WT (IC50: 4.59nM), L1196M (2.07nM), G1202R (5.95nM); curbs Karpas299, H2228 cell growth; for ALCL research.</p>Formule :C35H45ClN6O6S4Couleur et forme :SolidMasse moléculaire :809.48Tyrphostin 51
CAS :<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Formule :C13H8N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :268.23GDC-0834 S-enantiomer
CAS :<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Formule :C33H36N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :596.74Atopaxar
CAS :<p>Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Formule :C29H38FN3O5Degré de pureté :97.07% - 98.07%Couleur et forme :SolidMasse moléculaire :527.63JNJ28871063 hydrochloride
CAS :<p>ErbB receptor family inhibitor</p>Formule :C24H28Cl2N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :519.42AAE871
CAS :<p>AAE871 is a type I FLT3 inhibitor.</p>Formule :C24H34N8O2SCouleur et forme :SolidMasse moléculaire :498.64pan-HER-IN-1
CAS :<p>Compound C5: Irreversible, oral pan-HER inhibitor with low IC50s for EGFR/HERs; induces apoptosis and has antitumor effects.</p>Formule :C19H14BrN5OCouleur et forme :SolidMasse moléculaire :408.25Nuvenzepine
CAS :<p>Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.</p>Formule :C19H20N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :336.39HS-438
CAS :<p>HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.</p>Formule :C17H17N3O3SCouleur et forme :SolidMasse moléculaire :343.4EL-102
CAS :<p>EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer.</p>Formule :C19H16N2O3S2Degré de pureté :99.34%Couleur et forme :SolidMasse moléculaire :384.47Sch 13835
CAS :<p>Sch 13835 is an inhibitor of platelet derived growth factor.</p>Formule :C15H10ClNO4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :335.76EGFR-IN-64
CAS :<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formule :C20H21N3O3Couleur et forme :SolidMasse moléculaire :351.4Atopaxar Hydrobromide
CAS :<p>Atopaxar, a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling.</p>Formule :C29H39BrFN3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :608.54TG 100801 Hydrochloride
CAS :<p>TG 100801: prodrug for macular degeneration. TG 100572: inhibits kinases (VEGFRs, FGFRs, PDGFRβ, Src family), with varying IC50s.</p>Formule :C33H31Cl2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :616.54MAX-40279 hemifumarate
CAS :<p>MAX-40279 hemifumarate inhibits FLT3 and FGFR kinases, showing promise for AML treatment.</p>Formule :C48H50F2N12O6S2Couleur et forme :SolidMasse moléculaire :993.12BCR-ABL-IN-2
CAS :<p>BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).</p>Formule :C24H25Cl2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.39BLK-IN-2
CAS :<p>BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。</p>Formule :C39H41N9O3Couleur et forme :SolidMasse moléculaire :683.8TM-233
CAS :<p>TM-233 is an inhibitor of both JAK/STAT and proteasome activities that acts by inducing cell death in myeloma cells.</p>Formule :C25H20O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :384.42EGFR-IN-56
CAS :<p>EGFR-IN-56 (13a) inhibits EGFR, EGFRT790M (IC50: 541.7nM), EGFRT790M/L858R (IC50: 132.1nM), blocks G2/M phase, and triggers apoptosis.</p>Formule :C23H22N4O3SCouleur et forme :SolidMasse moléculaire :434.51JAK3-IN-12
CAS :<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Formule :C19H19N5O4SCouleur et forme :SolidMasse moléculaire :413.45Ilorasertib hydrochloride
CAS :<p>Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:</p>Formule :C25H22ClFN6O2SDegré de pureté :98.45%Couleur et forme :SolidMasse moléculaire :525HSP90-IN-13
CAS :<p>HSP90-IN-13 (5k): potent HSP90 inhibitor, IC50 25.07 nM, targets EGFR/VEGFR-2/Topo-2, blocks MCF-7 G2/M cycle, induces apoptosis.</p>Formule :C26H21N5O3SCouleur et forme :SolidMasse moléculaire :483.54M1002
CAS :<p>M1002, a HIF-2 agonist, boosts HIF-2alpha/ARNT activation and alters HIF-281alpha PAS-B, working with PHD inhibitors.</p>Formule :C15H8F6N2O2SDegré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :394.29Tyk2-IN-5
CAS :<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Formule :C21H19FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :434.43JBJ-04-125-02
CAS :<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61VEGFR-2-IN-19
CAS :<p>VEGFR-2-IN-19 (15b) effectively inhibits VEGFR2, induces apoptosis, and increases oxidative stress, showing potential as an anticancer drug.</p>Formule :C21H19N3O2Couleur et forme :SolidMasse moléculaire :345.39BPTQ
CAS :<p>BPTQ: DNA intercalator, halts cancer cell growth by blocking S/G2/M phases.</p>Formule :C17H16N4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :308.4FAK-IN-8
CAS :<p>FAK-IN-8 (compound 5h), a FAK inhibitor with an IC50 of 5.32 μM, exhibits potent anti-proliferative activity, making it suitable for use in cancer research [1].</p>Formule :C15H9Cl2N3O2SCouleur et forme :SolidMasse moléculaire :366.22ULK1-IN-2
CAS :<p>ULK1-IN-2, a potent anticancer agent, inhibits ULK1, induces apoptosis, blocks autophagy, and shows high cytotoxicity with an IC50 of 1.94 μM in A549 cells.</p>Formule :C19H16BrFN4O6Degré de pureté :99.25% - 99.25%Couleur et forme :SolidMasse moléculaire :495.26R916562
CAS :<p>R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.</p>Formule :C26H30ClN9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :536.09AZM475271
CAS :<p>AZM475271 is a potent and selective inhibitor of Src kinase(IC50 : 5 nM)</p>Formule :C23H27ClN4O3Degré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :442.94(R)-Afatinib
CAS :<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Formule :C24H25ClFN5O3Couleur et forme :SolidMasse moléculaire :485.94MAX-40279 hemiadipate
CAS :<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Formule :C50H56F2N12O6S2Couleur et forme :SolidMasse moléculaire :1023.19TX-1123
CAS :<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Formule :C20H24O3Couleur et forme :SolidMasse moléculaire :312.4NSC-689857
CAS :<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Formule :C25H29NO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.5EGFR/HER2/CDK9-IN-2
CAS :<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formule :C23H20N4O5S2Couleur et forme :SolidMasse moléculaire :496.56GDC-0834 Racemate
CAS :<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Formule :C33H36N6O3SCouleur et forme :SolidMasse moléculaire :596.74OD36
CAS :<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Formule :C16H15ClN4O2Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :330.77GW768505A free base
CAS :<p>GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.</p>Formule :C27H19F4N5O3Couleur et forme :SolidMasse moléculaire :537.47JAK3/BTK-IN-5
CAS :<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Formule :C19H22ClN7O2Couleur et forme :SolidMasse moléculaire :415.88T-1840383
CAS :<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formule :C30H25ClFN5O4Couleur et forme :SolidMasse moléculaire :574PD 166326
CAS :<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Formule :C21H16Cl2N4O2Couleur et forme :SolidMasse moléculaire :427.28TG 100572
CAS :<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Formule :C26H26ClN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :475.97LBW242
CAS :<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Formule :C27H42N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :454.65Syk-IN-1
CAS :<p>Syk-IN-11 is a selective Syk inhibitor.</p>Formule :C18H22N8OCouleur et forme :SolidMasse moléculaire :366.42SB-633825
CAS :<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Formule :C28H25N3O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.58OICR-0547
CAS :<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Formule :C28H29F3N4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :542.55ALK2-IN-5
CAS :<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Formule :C24H32N8O2Couleur et forme :SolidMasse moléculaire :464.56Depatuxizumab mafodotin
CAS :<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Couleur et forme :LiquidVEGFR-2-IN-20
CAS :<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Formule :C20H20N4O3SCouleur et forme :SolidMasse moléculaire :396.46PF-00337210
CAS :<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Formule :C26H27N3O5Couleur et forme :SolidMasse moléculaire :461.51EGFR-IN-89
CAS :<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formule :C26H31FN8O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :538.64Gefitinib N-oxide
CAS :<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formule :C22H24ClFN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.9Ibrutinib-MPEA
CAS :<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Formule :C32H39N9O2Couleur et forme :SolidMasse moléculaire :581.71BIIB-057
CAS :<p>BIIB-057 is a selective Syk inhibitor.</p>Formule :C19H23N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :393.45Sitravatinib malate
CAS :<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Formule :C37H35F2N5O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :763.76VEGFR-2-IN-27
CAS :<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Formule :C25H21FN4O4Couleur et forme :SolidMasse moléculaire :460.46CP-547632 hydrochloride
CAS :<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Formule :C20H25BrClF2N5O3SCouleur et forme :SolidMasse moléculaire :568.86FLT3/ITD-IN-3
CAS :<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Formule :C22H26ClN7O2Couleur et forme :SolidMasse moléculaire :455.94WY-135
CAS :<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Formule :C28H34ClN9O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :612.15FIIN-4
CAS :<p>FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.</p>Formule :C35H38N8O4Degré de pureté :>99.99%Couleur et forme :SolidMasse moléculaire :634.73EP009
CAS :<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formule :C14H24O2Couleur et forme :SolidMasse moléculaire :224.34AG1433
CAS :<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Formule :C16H15ClN2O2Couleur et forme :SolidMasse moléculaire :302.76EGFR-IN-51
CAS :<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Formule :C21H15N3O2SCouleur et forme :SolidMasse moléculaire :373.43CHMFL-ABL/KIT-155
CAS :<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Formule :C33H38F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :609.68Tyk2-IN-7
CAS :<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formule :C18H15D3N6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :401.46MS-1020
CAS :<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formule :C21H18N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :346.38Cenisertib
CAS :<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Formule :C24H30FN7OCouleur et forme :SolidMasse moléculaire :451.541,2,3,4,5,6-Hexabromocyclohexane
CAS :<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formule :C6H6Br6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :557.54MS 39
CAS :<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formule :C55H71ClFN9O7SCouleur et forme :SolidMasse moléculaire :1056.72PF-06651481-00
CAS :<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Formule :C26H29Cl2N5O3Degré de pureté :97.01%Couleur et forme :SolidMasse moléculaire :530.45INCB16562
CAS :<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formule :C19H11Cl2N5Couleur et forme :SolidMasse moléculaire :380.23Jaspamycin
CAS :<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formule :C12H12N4O5Couleur et forme :SolidMasse moléculaire :292.25FLT3-IN-12
CAS :<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Formule :C21H23F3N6OCouleur et forme :SolidMasse moléculaire :432.44JAK3-IN-9
CAS :<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Formule :C17H23N5O4SCouleur et forme :SolidMasse moléculaire :393.46ALK5-IN-29
CAS :<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Formule :C24H25FN8Couleur et forme :SolidMasse moléculaire :444.51NVP-AAD777
CAS :<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Formule :C22H14F6N4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.36VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Formule :C26H20Cl2F3N5O3S2Couleur et forme :SolidMasse moléculaire :642.5XST-14
CAS :<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Formule :C16H21NO4Degré de pureté :99.84% - 99.84%Couleur et forme :SolidMasse moléculaire :291.34GZD856
CAS :<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Formule :C29H27F3N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :532.56KRN383
CAS :<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Formule :C17H17N3O4Couleur et forme :SolidMasse moléculaire :327.33
